News

Home News World

Regulator raps Johnson & Johnson for presence of cancer-causing substance in 'No More Tears' baby shampoo

Regulator raps Johnson & Johnson for presence of cancer-causing substance in 'No More Tears' baby shampoo

US healthcare major Johnson and Johnson (J&J) has arrived in a bad position once more with Indian wellbeing controllers as its renowned 'No More Tears' infant cleanser was found to have a malignant growth causing substance in quality tests led by Drug Control Organization of Rajasthan. 

Two groups of the cleanser produced at J&J's office in Baddi, Himachal Pradesh, supposedly contained formaldehyde more than expressed by the organization. 

The Rajasthan tranquilize controller issued a notice on March 31 saying that cleanser bottles from these clusters must be removed the racks. In the notice, the expert referenced that specific examples are "not of standard quality". 

 

A J&J representative rejected the reports saying that the organization does not acknowledge between time results. "The legislature did not uncover the test strategies, subtleties or any discoveries. This is disturbing, particularly when there is no endorsed test technique for testing formaldehyde. We have affirmed to the Indian specialists that we don't include formaldehyde as a fixing in our cleanser," the individual included. 

The New York Times had announced in January 2014 of a comparative emergency, when J&J needed to upgrade its shampoos and different items after buyers brought worries about formaldehyde up in its items. 

This comes soon after Johnson's child powder was under the administrative focal point for conceivably having asbestos, another disease causing substance. Simply a month ago, government organizations gave it a green light to continue the powder's generation. 

The legislature began testing different items from J&J after a report by Reuters asserted that the organization knew about the cancer-causing agents in its items however concealed the data from the general population. 

J&J as of late needed to spend a pay worth Rs 74 lakh to a casualty of the organization's flawed hip inserts. These inserts purportedly prompted resulting medical procedures for patients, some of whom were gravely harmed.

Comments